Andrew Loblaw

7PUBLICATIONS
43CO-AUTHORS
Predictive and prognostic markersRadiation therapyMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 27, 2026
Population-Level Resources and Costs Associated with Low-Risk Prostate Cancer Patients on Active Surveillance.

|Apr 27, 2026
The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review.

|Dec 24, 2025
Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies.

Jennifer Le Guevelou, Thomas Zilli, Federica Ferrario

|Jan 17, 2025
Prognostic value of MR visibility/invisibility in men on Active Surveillance.

Laurence Klotz, Andrew Loblaw, Liying Zhang

|Aug 21, 2024
The Proteogenomics of Prostate Cancer Radioresistance.

Roni Haas, Gavin Frame, Shahbaz Khan

|Nov 03, 2023
The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus?

Wee Loon Ong, Andrew Loblaw

Pageof 2

Frequent Collaborators

1 joint publications

Jeremy Grummet

1 joint publications

Mark Emberton

1 joint publications

Roni Haas

1 joint publications

Gavin Frame